Boston Scientific has completed its acquisition of a division of the Lowell-based electrophysiology business of C.R. Bard, which the Natick-based medical device manufacturer said could significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures.
The acquisition, which Boston Scientific (BSX) announced in June, enables the company to provide a broader portfolio of electrophysiology tools, including products for cardiac catheter surgeries. The addition of Bard’s electrophysiology global business in advanced therapeutic catheters, diagnostic catheters, electrophysiology recording systems and intra-cardiac access devices gives Boston Scientific additional scale and scope to serve a $2.5-billion EP market that’s growing at nearly 10 percent aeach year, according to a BSX statement.
When the deal was announced in June, BSX said it would pay Bard $275 million in cash.
BSX said it expects the transaction to have no major impact on adjusted earnings per share this year, but will add one cent per share in 2014.
Read more
